{"created":"2023-07-27T06:55:20.319074+00:00","id":51140,"links":{},"metadata":{"_buckets":{"deposit":"2f740b51-48e9-49de-9775-963ea5b14dae"},"_deposit":{"created_by":18,"id":"51140","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"51140"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00051140","sets":["2812:2813:4085"]},"author_link":["115","22513"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-05-18","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"22p.","bibliographicVolumeNumber":"2019-04-01 - 2022-03-31","bibliographic_titles":[{"bibliographic_title":"令和3(2021)年度 科学研究費補助金 基盤研究(B) 研究成果報告書"},{"bibliographic_title":"2021 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Accumulation of 131I-MIBG in the neuroblastoma cell lines, SK-N-SH and SK-N-F1, were determined to be the saturable active transport through upytake-1 mechanism on cells in contrast that in nonspecific cells depended on non-saturable uptake. Vmax of this mechanism on the cells was determined. Analysis by flow-cytometry revealed PD-L1 expression on SK-N-F1 cells but not on SK-N-SH cells. However, its expression after irradiation was controversially upregulated in SK-N-SH cells but not in SK-N-F1 cells. The combined use of internal radiation therapy and immune therapy may be valuable in the treatment of neuroblastoma patients.","subitem_description_type":"Abstract"},{"subitem_description":"神経芽腫細胞SK-N-SH、SK-N-F1において、131I-MIBG取り込みはuptake-1による能動的取り込みで飽和機序を認めるのに対し、非特異的細胞では非飽和機序であった。また、各細胞における取り込み速度Vmaxを確認した。PD-L1発現をフローサイトメトリーにて解析したところ、SH細胞では発現しておらず、F細胞の発現を確認した。F細胞およびSH細胞はCD45-CD56+にて同定できた。それぞれの細胞株のX線照射時のPD-L1発現を検討した結果、F細胞では発現増強は認められなかったが、SH細胞ではX線照射によりPD-L1の発現増強を認め、内照射と免疫療法併用意義が示唆された。","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:19H03598, 研究期間(年度):2019-04-01 - 2022-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「高リスク化学療法不応性神経芽腫に対する新治療戦略の開発」課題番号19H03598\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-19H03598/19H03598seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00057443","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=20281024"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=20281024","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19H03598/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19H03598/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-19H03598/19H03598seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-19H03598/19H03598seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"絹谷, 清剛"}],"nameIdentifiers":[{"nameIdentifier":"115","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"20281024","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=20281024"},{"nameIdentifier":"20281024","nameIdentifierScheme":"金沢大学研究者情報","nameIdentifierURI":"http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=20281024"},{"nameIdentifier":"20281024","nameIdentifierScheme":"研究者番号","nameIdentifierURI":"https://nrid.nii.ac.jp/nrid/1000020281024"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-02-02"}],"displaytype":"detail","filename":"ME-PR-KINUYA-S-kaken 2022-22p.pdf","filesize":[{"value":"175.5 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-KINUYA-S-kaken 2022-22p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/51140/files/ME-PR-KINUYA-S-kaken 2022-22p.pdf"},"version_id":"02870105-bdf3-4775-80d9-082d75b346c6"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"高リスク化学療法不応性神経芽腫に対する新治療戦略の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"高リスク化学療法不応性神経芽腫に対する新治療戦略の開発"},{"subitem_title":"Development of new therapeutoc strategy for high-risk chemotherapy-refractory neuroblastoma","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["4085"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-02-02"},"publish_date":"2023-02-02","publish_status":"0","recid":"51140","relation_version_is_last":true,"title":["高リスク化学療法不応性神経芽腫に対する新治療戦略の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-07-01T05:18:05.571651+00:00"}